-
Je něco špatně v tomto záznamu ?
p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration
C. Turnquist, I. Horikawa, E. Foran, EO. Major, B. Vojtesek, DP. Lane, X. Lu, BT. Harris, CC. Harris,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
NLK
Free Medical Journals
od 2011
PubMed Central
od 2011 do Před 1 rokem
Europe PubMed Central
od 2011 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
PubMed
27104929
DOI
10.1038/cdd.2016.37
Knihovny.cz E-zdroje
- MeSH
- alternativní sestřih MeSH
- Alzheimerova nemoc metabolismus patologie MeSH
- amyotrofická laterální skleróza metabolismus patologie MeSH
- astrocyty cytologie účinky léků metabolismus MeSH
- autofagie účinky léků MeSH
- genetické vektory genetika metabolismus MeSH
- interleukin-6 genetika metabolismus MeSH
- kokultivační techniky MeSH
- kultivované buňky MeSH
- leupeptiny farmakologie MeSH
- lidé MeSH
- malá interferující RNA metabolismus MeSH
- mozek metabolismus patologie MeSH
- nádorový supresorový protein p53 antagonisté a inhibitory genetika metabolismus MeSH
- neurony cytologie metabolismus MeSH
- neuroprotekce fyziologie MeSH
- protein - isoformy antagonisté a inhibitory genetika metabolismus MeSH
- RNA interference MeSH
- sekvestosom 1 antagonisté a inhibitory genetika metabolismus MeSH
- serin-arginin sestřihové faktory antagonisté a inhibitory genetika metabolismus MeSH
- stárnutí buněk MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
Bidirectional interactions between astrocytes and neurons have physiological roles in the central nervous system and an altered state or dysfunction of such interactions may be associated with neurodegenerative diseases, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Astrocytes exert structural, metabolic and functional effects on neurons, which can be either neurotoxic or neuroprotective. Their neurotoxic effect is mediated via the senescence-associated secretory phenotype (SASP) involving pro-inflammatory cytokines (e.g., IL-6), while their neuroprotective effect is attributed to neurotrophic growth factors (e.g., NGF). We here demonstrate that the p53 isoforms Δ133p53 and p53β are expressed in astrocytes and regulate their toxic and protective effects on neurons. Primary human astrocytes undergoing cellular senescence upon serial passaging in vitro showed diminished expression of Δ133p53 and increased p53β, which were attributed to the autophagic degradation and the SRSF3-mediated alternative RNA splicing, respectively. Early-passage astrocytes with Δ133p53 knockdown or p53β overexpression were induced to show SASP and to exert neurotoxicity in co-culture with neurons. Restored expression of Δ133p53 in near-senescent, otherwise neurotoxic astrocytes conferred them with neuroprotective activity through repression of SASP and induction of neurotrophic growth factors. Brain tissues from AD and ALS patients possessed increased numbers of senescent astrocytes and, like senescent astrocytes in vitro, showed decreased Δ133p53 and increased p53β expression, supporting that our in vitro findings recapitulate in vivo pathology of these neurodegenerative diseases. Our finding that Δ133p53 enhances the neuroprotective function of aged and senescent astrocytes suggests that the p53 isoforms and their regulatory mechanisms are potential targets for therapeutic intervention in neurodegenerative diseases.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18011252
- 003
- CZ-PrNML
- 005
- 20180418124821.0
- 007
- ta
- 008
- 180404s2016 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/cdd.2016.37 $2 doi
- 035 __
- $a (PubMed)27104929
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Turnquist, C $u Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- 245 10
- $a p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration / $c C. Turnquist, I. Horikawa, E. Foran, EO. Major, B. Vojtesek, DP. Lane, X. Lu, BT. Harris, CC. Harris,
- 520 9_
- $a Bidirectional interactions between astrocytes and neurons have physiological roles in the central nervous system and an altered state or dysfunction of such interactions may be associated with neurodegenerative diseases, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Astrocytes exert structural, metabolic and functional effects on neurons, which can be either neurotoxic or neuroprotective. Their neurotoxic effect is mediated via the senescence-associated secretory phenotype (SASP) involving pro-inflammatory cytokines (e.g., IL-6), while their neuroprotective effect is attributed to neurotrophic growth factors (e.g., NGF). We here demonstrate that the p53 isoforms Δ133p53 and p53β are expressed in astrocytes and regulate their toxic and protective effects on neurons. Primary human astrocytes undergoing cellular senescence upon serial passaging in vitro showed diminished expression of Δ133p53 and increased p53β, which were attributed to the autophagic degradation and the SRSF3-mediated alternative RNA splicing, respectively. Early-passage astrocytes with Δ133p53 knockdown or p53β overexpression were induced to show SASP and to exert neurotoxicity in co-culture with neurons. Restored expression of Δ133p53 in near-senescent, otherwise neurotoxic astrocytes conferred them with neuroprotective activity through repression of SASP and induction of neurotrophic growth factors. Brain tissues from AD and ALS patients possessed increased numbers of senescent astrocytes and, like senescent astrocytes in vitro, showed decreased Δ133p53 and increased p53β expression, supporting that our in vitro findings recapitulate in vivo pathology of these neurodegenerative diseases. Our finding that Δ133p53 enhances the neuroprotective function of aged and senescent astrocytes suggests that the p53 isoforms and their regulatory mechanisms are potential targets for therapeutic intervention in neurodegenerative diseases.
- 650 _2
- $a alternativní sestřih $7 D017398
- 650 _2
- $a Alzheimerova nemoc $x metabolismus $x patologie $7 D000544
- 650 _2
- $a amyotrofická laterální skleróza $x metabolismus $x patologie $7 D000690
- 650 _2
- $a astrocyty $x cytologie $x účinky léků $x metabolismus $7 D001253
- 650 _2
- $a autofagie $x účinky léků $7 D001343
- 650 _2
- $a mozek $x metabolismus $x patologie $7 D001921
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a stárnutí buněk $7 D016922
- 650 _2
- $a kokultivační techniky $7 D018920
- 650 _2
- $a genetické vektory $x genetika $x metabolismus $7 D005822
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-6 $x genetika $x metabolismus $7 D015850
- 650 _2
- $a leupeptiny $x farmakologie $7 D007976
- 650 _2
- $a neurony $x cytologie $x metabolismus $7 D009474
- 650 _2
- $a neuroprotekce $x fyziologie $7 D000066829
- 650 _2
- $a protein - isoformy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D020033
- 650 _2
- $a RNA interference $7 D034622
- 650 _2
- $a malá interferující RNA $x metabolismus $7 D034741
- 650 _2
- $a sekvestosom 1 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000071456
- 650 _2
- $a serin-arginin sestřihové faktory $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000068103
- 650 _2
- $a nádorový supresorový protein p53 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Horikawa, I $u Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- 700 1_
- $a Foran, E $u Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
- 700 1_
- $a Major, E O $u Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
- 700 1_
- $a Vojtesek, B $u Regional Centre for Applied and Molecular Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic.
- 700 1_
- $a Lane, D P $u p53 Laboratory, Biomedical Sciences Institutes (A*STAR), Singapore 138648, Singapore.
- 700 1_
- $a Lu, X $u Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, UK.
- 700 1_
- $a Harris, B T $u Department of Neurology, Georgetown University Medical Center, Washington DC 20007, USA. Department of Pathology, Georgetown University Medical Center, Washington DC 20007, USA.
- 700 1_
- $a Harris, C C $u Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- 773 0_
- $w MED00005364 $t Cell death and differentiation $x 1476-5403 $g Roč. 23, č. 9 (2016), s. 1515-28
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27104929 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180418124921 $b ABA008
- 999 __
- $a ok $b bmc $g 1288737 $s 1008064
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 23 $c 9 $d 1515-28 $e 20160422 $i 1476-5403 $m Cell death and differentiation $n Cell Death Differ $x MED00005364
- LZP __
- $a Pubmed-20180404